Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2011

View Archived Issues

Eribulin prolongs survival of patients with breast cancer in EMBRACE trial

HIV vaccine MVA-B is safe and appears immunogenic in healthy subjects

Vadimezan exhibits therapeutic and prophylactic antiviral effects in preclinical study

Threshold Pharma identifies new 14-aminocamptothecins with potential as cancer therapeutics

Overexpression of fatty acid synthase correlates with high-risk GIST

Basilea Pharma patents new inhibitors of cAMP-specific 3',5'-cyclic phosphodiesterase 4

Anacor Pharma synthesizes new boron-containing antiprotozoal agents

Mitsubishi Tanabe and sanofi-aventis present new GSK-3 beta inhibitors

Phylogica and University of Cambridge to form spin-off Phenomica

New FGFR-2 activators reported by sanofi-aventis

Fresenius Biotech receives German approval to use ATG-Fresenius S in stem cell transplantation

Aeterna Zentaris and Yakult Honsha enter exclusive agreement for perifosine in Japan

Combination of Chk1 inhibitor and gemcitabine shows promise in model of colon cancer

Salix Pharma receives complete response letter for Xifaxan sNDA for non-constipation-predominant IBS

Xeplion is approved in Europe for schizophrenia

FDA removes clinical hold on AT-2220 for Pompe's disease

Global Health Ventures completes trials comparing lX-Excite to Viagra

Pfizer's axitinib receives European orphan drug status in renal cell carcinoma

Fibrocell Science and UCLA join to advance dermal fibroblast cell therapy

Biovest's BiovaxID receives E.U. orphan drug status in mantle cell lymphoma

GSK and HGS receive FDA approval for new lupus treatment Benlysta

Phase II trial of PD-0332991 in advanced NSCLC is under way

Auxilium Pharma reaches target enrollment in phase III Xiaflex trials in Peyronie's disease

Repligen's RG-2417 does not significantly improve symptoms of depression in phase IIb trial

Tyroxenex's X-82 enters phase I trial in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...